IP Library Granted Patent US 10,881,853
Granted Patent B2
US 10,881,853 · App. 16/153,472 · Granted Jan 5, 2021

Transcutaneous neuromodulation system and methods of using same

Inventors: Victor Reggie Edgerton (Los Angeles, CA); Yury P. Gerasimenko (Los Angeles, CA); Nicholas A. Terrafranca (Laguna Niguel, CA); Parag Gad (Woodland Hills, CA)
Assignee: The Regents of the University of California, A California Corporation
A61N1/36003A61N1/0456A61N1/06A61N1/36025A61N1/3616A61N1/36171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,881,853
App. No.
16/153,472
Granted
Jan 5, 2021
Kind
B2
Abstract

Neuromodulation systems are described comprising a signal generator and at least one electrode. The at least one electrode can be configured to deliver a stimulation to a mammal, wherein the stimulation includes a biphasic signal and an overlapping high frequency pulse thereby inducing voluntary movement in the individual. Methods of administering the stimulation are also described.

Claims (36)

1. A neuromodulation system comprising:

a processor;

a signal generator; and

at least one electrode,

wherein the processor, in cooperation with the signal generator and the at least one electrode are configured to deliver a transcutaneous stimulation to a mammal, the transcutaneous stimulation for inducing voluntary movement in the mammal and including:

during a first time period, a transcutaneous electrical spinal cord stimulation (“tESCS”) applied to the mammal during physical conditioning of the mammal,

during a second time period after the first time period, the tESCS applied to the mammal during reduced or no physical conditioning of the mammal, and

during a third time period after the second time period, the tESCS applied to the mammal during the physical conditioning of the mammal in conjunction with pharmacological enabling motor control (“fEmc”), and

wherein the tESCS applied during the first time period and the second time period is used to establish a functional baseline of the mammal.

2. The neuromodulation system of claim 1 , wherein the mammal is a human.

3. The neuromodulation system of claim 1 , wherein the voluntary movement is of a foot, a toe, a leg, an arm, a hand, a finger, a waist, or a combination thereof.

4. The neuromodulation system of claim 1 , wherein the voluntary movement comprises at least one of standing, stepping, a walking motor pattern, sitting down, laying down, reaching, grasping, pulling and pushing, swallowing and chewing, breathing, and coughing.

5. The neuromodulation system of claim 1 , wherein the tESCS includes a 0.5-100 Hz signal.

6. The neuromodulation system of claim 5 , wherein the tESCS is delivered at 0.5-200 mA.

7. The neuromodulation system of claim 1 , wherein the tESCS includes a 10 kHz overlapping high frequency pulse.

8. The neuromodulation system of claim 1 , wherein the tESCS includes a 5 kHz overlapping high frequency pulse.

9. The neuromodulation system of claim 1 , wherein the tESCS is applied over a cervical portion of a spinal cord or a brainstem via the at least one electrode.

10. The neuromodulation system of claim 1 , wherein the tESCS is applied paraspinally over at least one of a lumbar portion, a lumbosacral portion, and a sacral portion of a spinal cord.

11. The neuromodulation system of claim 1 , wherein the tESCS is applied over a T11-T12 vertebrae.

12. The neuromodulation system of claim 1 , wherein the mammal has a neurodegenerative brain injury.

13. The neuromodulation system of claim 12 , wherein the neurodegenerative brain injury is associated with a condition selected from the group consisting of Parkinson's disease, Huntington's disease, Alzheimer's, ischemia, stroke, dystonia, amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), or cerebral palsy.

14. A method of inducing a voluntary movement in a mammal with a spinal injury, the method comprising:

applying a stimulation to the mammal using a transcutaneous neuromodulation system for inducing the voluntary movement,

wherein the stimulation is applied by:

during a first time period, providing a transcutaneous electrical spinal cord stimulation (“tESCS”) to the mammal during physical conditioning of the mammal, and

during a second time period after the first time period, providing the tESCS to the mammal during the physical conditioning of the mammal in conjunction with pharmacological enabling motor control (“fEmc”), and

wherein the tESCS applied during the first time period is used to establish a functional baseline of the mammal.

15. The method of claim 14 , wherein the transcutaneous neuromodulation system includes:

a processor;

a signal generator; and

at least one electrode.

16. The method of claim 14 , wherein the tESCS includes a 0.5-100 Hz signal.

17. The method of claim 16 , wherein the tESCS is delivered at 0.5-200 mA.

18. The method of claim 14 , wherein the tESCS includes a 10 kHz overlapping high frequency pulse.

19. The method of claim 14 , wherein the tESCS includes a 5 kHz overlapping high frequency pulse.

20. The method of claim 14 , wherein the voluntary movement is of a leg, a foot, a toe, an arm, a hand, a finger, a leg, a waist, or a combination thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2020
From: NEURORECOVERY TECHNOLOGIES, INC.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION
Reel/Frame 053621/0220 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2019
From: EDGERTON, VICTOR REGGIE; GERASIMENKO, YURY P.; GAD, PARAG
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 050186/0500 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2019
From: TERRAFRANCA, NICHOLAS A.
To: NEUROENABLING TECHNOLOGIES, INC.
Reel/Frame 050186/0544 →
Continuity (5)
Continuation 14925791 · Oct 28, 2015
Continuation In Part 14357481
Provisional Application 62069590 · Oct 28, 2014
Provisional Application 61559025 · Nov 11, 2011
Related Publication 20190308017A1 · Oct 10, 2019
Cited By (7)
US 12,201,833 US 12,357,828 US 12,415,079 US 12,613,624 US 12,623,080 US 12,649,062 US 12,708,775